Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea

Background. Menstrual related migraine (MRM) occurs in 60% of women with migraine. These attacks are characterized by high intensity and poor response to abortive and prophylactic treatment. Hormonal therapy is one of the main treatment methods, but it has a large number of limitations. Increase in...

Full description

Bibliographic Details
Published in:	Клинический разбор в общей медицине
Main Authors:	Anna V. Berdnikova, Natalya B. Kadymova, Nina V. Latysheva, Margarita V. Naprienko, Elena G. Filatova
Format:	Article
Language:	English
Published:	LLC "MEDIAFORMAT" 2023-10-01
Subjects:	migraine monoclonal antibodies erenumab fremanezumab cgrp menstrual-related migraine
Online Access:	https://klin-razbor.ru/en/archive/2023/vol-4-10-2023/anti-cgrp-monoclonal-antibodies-in-the-treatment-of-migraine-in-women-impact-on-menstrual-relared-mi_6624/?element

Similar Items

A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
by: Caroline S. Casey, et al.
Published: (2025-04-01)

Efficacy of fremanezumab in patients with chronic migraine and concomitant depression
by: A.Y. Timokhovich, et al.
Published: (2024-10-01)

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?
by: Sena Uzun, et al.
Published: (2023-05-01)

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: V. Karpavičiūtė, et al.
Published: (2023-10-01)

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: V. Karpavičiūtė, et al.
Published: (2023-10-01)

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
by: Licia Grazzi, et al.
Published: (2024-02-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

Efficacy of anti-calcitonin gene-related peptide monoclonal antibodies in hemiplegic migraine: a case report and review of literature
by: Máté Héja, et al.
Published: (2025-04-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
by: Larry Charleston, et al.
Published: (2023-08-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
by: Edoardo Caronna, et al.
Published: (2021-10-01)

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody
by: Larisa A. Dobrynina, et al.
Published: (2023-06-01)

Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
by: Armin Scheffler, et al.
Published: (2024-07-01)

Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023-04-01)

The course of headache after the end of treatment with erenumab in patients with episodic and chronic migraine
by: Anna A. Garmanova, et al.
Published: (2024-05-01)

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
by: Giuseppe Tringali, et al.
Published: (2020-10-01)

Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study
by: Danilo Antonio Montisano, et al.
Published: (2024-04-01)

Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
by: Taoufik Alsaadi, et al.
Published: (2024-02-01)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-03-01)

Erenumab efficacy predictors for chronic migraine
by: Nina V. Vashchenko
Published: (2022-02-01)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
by: Agaath Hedina Manickam, et al.
Published: (2021-08-01)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
by: Hugo Sevivas, et al.
Published: (2022-06-01)

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine
by: G. N. Belskaya, et al.
Published: (2024-02-01)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
by: Stewart J Tepper, et al.
Published: (2021-07-01)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
by: Bianca Raffaelli, et al.
Published: (2023-01-01)

Influence of Constipation in the Behavior of Circulating Alpha- and Beta-CGRP Levels in Chronic/High-Frequency Migraine Patients After CGRP Monoclonal Antibodies
by: Gabriel Gárate, et al.
Published: (2025-05-01)

Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis
by: Mohamed E. Haseeb, et al.
Published: (2025-03-01)

Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies
by: Dawn C. Buse, et al.
Published: (2025-05-01)

Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine
by: Giulia Ceccardi, et al.
Published: (2023-11-01)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
by: Piero Barbanti, et al.
Published: (2022-04-01)

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
by: M. T. Corasaniti, et al.
Published: (2023-12-01)

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
by: Christian Lampl, et al.
Published: (2024-12-01)

Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
by: Michael Lowe, et al.
Published: (2022-07-01)

One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study
by: M. Lanteri-Minet, et al.
Published: (2023-11-01)

Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine
by: Britt W. H. Van Der Arend, et al.
Published: (2024-04-01)

Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report
by: C. K. Cullum, et al.
Published: (2021-07-01)

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
by: Elizabeth Seng, et al.
Published: (2024-09-01)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
by: Andreas A. Argyriou, et al.
Published: (2022-12-01)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
by: Paolo Martelletti
Published: (2020-04-01)